Our Pricing

Understanding Oral Alternatives to Mounjaro for Weight Loss

Published: 11 September 2026

If you're considering an oral alternative to Mounjaro, you're exploring needle-free weight loss treatments that deliver similar clinical benefits without injections. Wegovy Oral Tablets, containing the same active ingredient (semaglutide) proven in major weight loss trials, offer a convenient pill-based option for patients seeking effective pharmacological support for obesity management. At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance on oral and injectable GLP-1 receptor agonists, ensuring you receive the most suitable treatment following a comprehensive online assessment by a qualified prescriber.

What Is the Best Oral Alternative to Mounjaro Available in the UK?

The most clinically effective oral alternative to Mounjaro currently available in the UK is Wegovy Oral Tablets, containing semaglutide in pill form [1]. While Mounjaro (tirzepatide) is administered as a weekly injection, Wegovy Oral Tablets provide a once-daily oral option that activates the same GLP-1 receptor pathways responsible for appetite suppression and improved glycaemic control. Clinical trials have demonstrated that oral semaglutide produces significant weight reduction, with participants achieving an average of 15-17% total body weight loss over 68 weeks when combined with lifestyle interventions [2].

At Cured Pharmacy, Wegovy Oral Tablets are available from £20 offering a cost-effective and needle-free option for patients who prefer not to self-inject. Both Wegovy Oral and Mounjaro injections require a prescription following clinical assessment by a UK-registered prescriber. Our online consultation takes under three minutes, and our team reviews your medical history, current medications, and weight loss goals to determine the most appropriate treatment. All medications dispensed are genuine, UK-licensed products sourced from MHRA-approved wholesalers, ensuring safety and regulatory compliance.

How Does an Oral Alternative to Mounjaro Work for Weight Loss?

An oral alternative to Mounjaro, such as Wegovy Oral Tablets, works by mimicking the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates appetite and blood sugar levels [3]. When you take oral semaglutide, it binds to GLP-1 receptors in the brain, particularly in areas controlling hunger and satiety, leading to reduced calorie intake and prolonged feelings of fullness after meals. This mechanism is identical to that of injectable semaglutide and similar to Mounjaro's dual GLP-1/GIP receptor activation, though tirzepatide's dual action may produce slightly greater weight loss in head-to-head trials [4].

The oral formulation uses a specialized absorption enhancer (SNAC) that protects semaglutide from stomach acid degradation and facilitates absorption across the gastric mucosa. Patients typically start on a low dose (3mg daily) and gradually titrate upwards over 16-20 weeks to a maintenance dose of 14mg daily, minimising gastrointestinal side effects such as nausea and allowing the body to adjust to the medication. This gradual dose escalation mirrors the approach used with injectable GLP-1 treatments and is essential for tolerability and adherence.

Comparing Mechanism of Action: Oral Semaglutide vs Tirzepatide

While oral semaglutide (Wegovy Oral) is a pure GLP-1 receptor agonist, Mounjaro (tirzepatide) is a dual GLP-1/GIP receptor agonist, meaning it activates two incretin pathways simultaneously. The additional GIP receptor activation may enhance insulin secretion, improve fat metabolism, and contribute to the slightly superior weight loss outcomes observed in the SURPASS-2 trial, where tirzepatide 15mg produced approximately 2-3% more total body weight loss than semaglutide 1mg over 40 weeks [4]. However, oral semaglutide remains a highly effective oral alternative to Mounjaro for patients prioritising needle-free administration, with robust clinical evidence supporting its use in obesity management.

Who Is Suitable for an Oral Alternative to Mounjaro?

An oral alternative to Mounjaro is suitable for adults with a body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. Wegovy Oral Tablets are licensed for chronic weight management in conjunction with a reduced-calorie diet and increased physical activity, making them appropriate for patients who have struggled to achieve meaningful weight loss through lifestyle changes alone. Oral semaglutide is particularly beneficial for individuals with needle phobia, those who travel frequently and prefer the convenience of a daily tablet, or patients who have experienced injection site reactions with subcutaneous GLP-1 therapies.

However, oral semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists have been associated with thyroid C-cell tumours in rodent studies [3]. It is also not recommended for individuals with severe gastrointestinal disease, including gastroparesis, or those with a history of pancreatitis. Pregnant or breastfeeding women should not use oral semaglutide, and treatment should be discontinued at least two months before a planned pregnancy. Our UK-registered prescribers conduct a thorough medical assessment during your online consultation to ensure oral alternatives to Mounjaro are safe and appropriate for your individual circumstances.

Assessing Patient Preference: Injections vs Oral Tablets

Patient preference plays a significant role in treatment adherence and long-term success with weight loss medications. While injectable Mounjaro requires only one administration per week, some patients find the prospect of self-injection daunting or inconvenient. Conversely, Wegovy Oral Tablets require daily dosing, which demands consistent adherence but eliminates needle-related concerns. During your consultation at Cured Pharmacy, our clinical team discusses your lifestyle, medication preferences, and any previous experience with GLP-1 therapies to recommend the most suitable oral alternative to Mounjaro or injectable option for your weight loss journey.

What Are the Side Effects of an Oral Alternative to Mounjaro?

The most common side effects of an oral alternative to Mounjaro, such as Wegovy Oral Tablets, are gastrointestinal in nature and include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [2]. These symptoms typically occur during the initial titration phase and often diminish as the body adapts to the medication. In clinical trials, approximately 44% of participants taking oral semaglutide reported nausea, compared to 17% in the placebo group, though most cases were mild to moderate in severity and resolved within a few weeks [2]. Taking the tablet on an empty stomach with a small amount of water (no more than 120ml) and waiting at least 30 minutes before eating or drinking further can help optimise absorption and reduce gastrointestinal upset.

Rarer but more serious side effects include acute pancreatitis, gallbladder disease, hypoglycaemia (particularly in patients also taking insulin or sulfonylureas), and potential thyroid tumours, as noted in preclinical studies [3]. Patients should seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction such as rash, swelling, or difficulty breathing. At Cured Pharmacy, our pharmacists provide comprehensive counselling on side effect management and are available via phone (+44 116 4646009) to address any concerns during your treatment with an oral alternative to Mounjaro.

How Much Does an Oral Alternative to Mounjaro Cost in the UK?

At Cured Pharmacy, Wegovy Oral Tablets—the leading oral alternative to Mounjaro—are priced from £124.99 per month, making them one of the most affordable prescription weight loss treatments available in the UK. New patients can save an additional £20 off their first order using the code Weightlossnew, reducing the initial cost to £124.99. This transparent, upfront pricing includes your medication, free online consultation with a UK-registered prescriber, and discreet home delivery. Unlike some providers who require long-term subscriptions or hidden fees, Cured Pharmacy offers flexible monthly ordering with no contractual obligations, allowing you to adjust or discontinue treatment as needed in consultation with your healthcare provider.

For comparison, injectable Mounjaro is priced from £124.99 at Cured Pharmacy, reflecting the higher cost of the dual GLP-1/GIP formulation and prefilled pen delivery system. While Mounjaro may produce slightly greater weight loss in clinical trials, the oral alternative to Mounjaro offers a more budget-friendly and needle-free option for patients seeking effective pharmacological weight management. All prices are inclusive of the clinical consultation and prescription, and our team ensures you receive the lowest price guarantee across the UK online pharmacy market.

Understanding the Cost-Benefit of Oral vs Injectable GLP-1 Therapies

When evaluating the cost-effectiveness of an oral alternative to Mounjaro versus injectable options, consider both the financial investment and the clinical outcomes. Oral semaglutide at £124.99 per month offers substantial value for patients achieving 15-17% total body weight loss over 68 weeks, translating to approximately £124.99-£124.99 annually [2]. Injectable Mounjaro, at £124.99 per month (£124.99 annually), may justify the additional cost for patients seeking maximal weight reduction or those who prefer once-weekly dosing. Our clinical team at Cured Pharmacy helps you weigh these factors during your consultation, ensuring your chosen oral alternative to Mounjaro aligns with both your health goals and budget.

How to Get Started with an Oral Alternative to Mounjaro at Cured Pharmacy

Getting started with an oral alternative to Mounjaro at Cured Pharmacy is straightforward and takes less than three minutes. Begin by completing our confidential online medical questionnaire, which covers your weight loss history, current medications, allergies, and any pre-existing medical conditions. Our UK-registered prescribers—led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073)—review your submission within hours and determine whether Wegovy Oral Tablets or another weight loss treatment is suitable for you. If approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and dispatched via Royal Mail in 100% discreet packaging, typically arriving within 1-3 working days.

Should our clinical team identify any contraindications or recommend an alternative treatment—such as injectable Mounjaro, Saxenda, or Orlistat—they will contact you directly to discuss your options. We prioritise patient safety and regulatory compliance, ensuring every prescription for an oral alternative to Mounjaro is issued only after thorough clinical assessment. For ongoing support, our pharmacists are available by phone during business hours to answer questions about dosing, side effects, or treatment adjustments. Start your assessment today and take the first step towards effective, needle-free weight loss with the UK's most trusted online pharmacy.

Scientific References

1. Wilding, J. P., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., ... & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 11 September 2026]
2. Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., ... & Garvey, W. T. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705-719. [accessed 11 September 2026]
3. Davies, M., Pieber, T. R., Hartoft-Nielsen, M. L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017). Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial. JAMA, 318(15), 1460-1470. [accessed 11 September 2026]
4. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 11 September 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 11 September 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 11 September 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 11 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.